focus -WSS

focus

author：entertainment 2025-09-06 04:17:34 - browse：6578

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： STAT Readout Newsletter: Today's biggest biotech updates

focus

WSS

STAT Summit: How a Chicago ER doctor tackles gun violence

Roche drug slashes death risk in early

Health tech investors get more selective as pandemic boom fades

How climate

Beam Therapeutics to lay off 20% of its staff, re

How AI can help patients find reliable information about doctors

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Malaria cases in Florida and Texas: Here’s what you need to know

How climate

Malaria cases in Florida and Texas: Here’s what you need to know

Study on Amgen’s bispecific immunotherapy produces positive data

As demand for Covid shots wanes, Moderna seeks its next success

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

ChatGPT in medicine: STAT answers readers' burning questions

Smaller biotechs seek to piggyback on weight loss drug boom

focus

UnitedHealth, Optum discontinue NaviHealth name

FDA clears Verve to begin U.S. study of gene

J&J lung cancer data amount to new salvo against AstraZeneca

Smaller biotechs seek to piggyback on weight loss drug boom

HHS leader on health, climate change and biopharma emissions

The EU Joint Clinical Assessment needs to live up to its promise

leisure time

focus

hotspot

entertainment